Mr. Trizzino is Senior Vice President, Chief Business Officer and Chief Financial Officer with responsibility for all pre-commercial and commercial launch strategy and execution, financial reporting, corporate funding, and investor/public relations. He had previously served as Senior Vice President, Commercial Operations beginning in 2014. Mr. Trizzino originally joined Novavax in 2009 with a broad range of experiences in small to large publicly-held companies. He has an extensive background in the vaccine market with previous roles overseeing commercialization, vaccine policy, strategic development, business development, financing, investor relations and public relations. In 2011, Mr. Trizzino joined Immunovaccine as its CEO, and successfully led the company into clinical development of its lead candidate, while securing the required funding commitments in the equity market as well as non-dilutive sources. Prior to his tenures at Novavax and Immunovaccine, Mr. Trizzino had leadership responsibilities at MedImmune, LLC, an AstraZeneca company, ID Biomedical and Henry Schein, Inc., all focused on infectious disease vaccine markets. Mr. Trizzino received his Bachelor of Science degree from Long Island University, CW Post and his Master of Business Administration degree from New York University, Stern School of Business.